CymaBay to Report First Quarter 2017 Financial Results on Thursday, May 11

NEWARK, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. CBAY, a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet medical need, today announced that it will host a conference call and live audio webcast on Thursday, May 11^th at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2017 and provide a business update.

Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13661044.  To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events. 

About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist. A Phase 2 study of seladelpar in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has completed Phase 2 studies for seladelpar in subjects with primary biliary cholangitis and homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications. Arhalofenate is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in subjects with gout. Arhalofenate has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc.  CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.

For additional Information about CymaBay visit www.cymabay.com.

Contact:	
Sujal Shah			
CymaBay Therapeutics, Inc.	
(510) 293-8800			
Investors@CymaBay.com	

Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
Hans@LifeSciAdvisors.com